3370 studies found for:    novartis
Show Display Options
Rank Status Study
21 Recruiting Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects
Condition: Meningococcal Disease
Intervention: Biological: rMenB+OMV
22 Recruiting Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine
Conditions: Influenza, Human;   Flu, Human;   Flu, Avian;   Influenza;   Influenza A Virus, H5N1 Subtype
Interventions: Biological: Novartis Investigational H5N1 vaccine;   Biological: Novartis Seasonal Influenza Vaccine
23 Completed Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal B Recombinant Vaccine in Adolescents Aged 11-17 Years
Condition: Meningococcal Disease
Interventions: Biological: Meningoccal B recombinat vaccine;   Biological: Meningococcal ACWY-CRM conjugate vaccine and placebo
24 Completed
Has Results
B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants
Condition: Meningococcal Disease
Interventions: Biological: MenACWY-CRM;   Biological: DTaP-Hib-IPV;   Biological: PCV;   Biological: MMR;   Biological: Hib
25 Completed Novartis Pandemic Influenza A (H1N1) Vaccine(s) Observational Comparative Safety Study
Condition: Influenza
Intervention: Other: Non-intervention observational study
26 Not yet recruiting Trial to Assess Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents
Condition: Meningococcal Disease
Interventions: Biological: rMenB+OMV;   Other: Placebo;   Biological: Hep A;   Biological: ABCWy
27 Recruiting Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions
Conditions: Influenza,;   Flu,
Interventions: Biological: Novartis Investigational H5N1 vaccine;   Biological: Novartis Seasonal Influenza Vaccine
28 Completed
Has Results
Novartis Vaccine and Diagnostics Carriage Trial
Condition: N. Meningitidis Carriage
Interventions: Biological: Meningococcal B Recombinant + OMV vaccine (rMenB +OMV NZ);   Biological: MenACWY-CRM conjugate vaccine;   Biological: Japanese Encephalitis vaccine
29 Completed
Has Results
Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers
Condition: Meningococcal Infections
Interventions: Biological: MenACWY-CRM + MMRV;   Biological: MMRV;   Biological: MenACWY-CRM
30 Completed
Has Results
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
Condition: Meningitis, Meningococcal
Interventions: Biological: Meningococcal ACWY Conjugate Vaccine;   Biological: DTaP-IPV-HBV;   Biological: Hib;   Biological: Rotavirus;   Biological: Pneumococcal 7-valent Conjugate Vaccine;   Biological: HAV;   Biological: MMR-V;   Biological: DTaP
31 Completed Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Condition: Meningococcal Disease
Interventions: Biological: Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1);   Biological: Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2);   Biological: Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3);   Biological: Routine vaccination;   Biological: Meningococcal group C
32 Completed Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers
Condition: Meningococcal Disease
Interventions: Biological: 1a - rMenB+OMV NZ and routine infant vaccinations;   Biological: 1b - rMenB+OMV NZ and routine infant vaccinations;   Biological: 2a - Routine infant vaccinations and rMenB+OMV NZ;   Biological: 2b - rMenB+OMV NZ and routine infant vaccinations;   Biological: 3a - rMenB+OMV NZ and routine infant vaccinations;   Biological: 3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations;   Biological: 4a- rMenB+OMV NZ and routine infant vaccinations;   Biological: 4b - rMenB+OMV NZ and routine infant vaccinations
33 Recruiting Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 11 to 55 Years of Age in the Republic of South Korea
Condition: Meningococcal Disease
Intervention: Biological: Novartis Meningococcal ACWY Conjugate Vaccine (Menveo)
34 Completed Bioequivalence of Vildagliptin Tablet Manufactured in China Compared to Imported Vildagliptin Tablet in Chinese Healthy Volunteers
Condition: Healthy
Intervention: Drug: Vildagliptin (LAF237)
35 Completed A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.
Condition: Prevention of the Meningococcal Disease
Intervention: Biological: rMenB+OMV NZ
36 Completed
Has Results
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Conditions: Meningitis;   Meningococcal Infection
Interventions: Biological: MenACWY-CRM197;   Biological: DTaP (Diptheria, Tetanus, Pertussis) Vaccine;   Biological: Hib (Haemophilus influenza b) Vaccine;   Biological: IPV (Inactivated Polio Vaccine) Vaccine;   Biological: Pneumococcal conjugate Vaccine;   Biological: MMR (Measles, Mumps, and Rubella) Vaccine;   Biological: Varicella Vaccine;   Biological: Hepatitis A Virus
37 Completed
Has Results
Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine
Condition: Meningococcal Disease
Intervention: Biological: MenACWY-CRM
38 Completed
Has Results
A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea
Conditions: Meningococcal Disease;   Meningococcal Meningitis
Interventions: Biological: Novartis MenACWY-CRM;   Biological: Saline Placebo
39 Completed Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Condition: Healthy
Intervention: Biological: Serogroup B meningococcal Vaccine
40 Completed Safety, Tolerability and Immunogenicity of Two Different Formulations of MenB Vaccine, When Administered to Healthy Infants
Condition: Meningococcal Disease
Intervention: Biological: Serogroup B meningococcal Vaccine

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years